finasteride biased the interpretation of the prostate biopsies.
finasteride improved sexual function but not voiding symptoms.
finasteride reduced the 7-year period prevalence of prostate cancer by 25%.
finasteride worked best in men with a positive family history.
more men who took finasteride died of prostate cancer than those who did not.
the effect of volume reduction on tumor detection.
the histologic effect of finasteride on tumor grade.
more men on placebo had high-grade cancers.
more men taking finasteride were sampled.
the effect of volume increase on tumor detection.
no significant difference in prostate cancer incidence in all four arms.
all of the above.
a significant increased incidence of diabetes mellitus in the selenium arm.
a significant increased incidence of prostate cancer in the vitamin E arm.
a significant reduction in the incidence of prostate cancer in the combination arm.
the pure form with other antioxidants.
the pure form as oral capsules.
low-grade prostate cancer.
surgical intervention for lower urinary tract symptoms.
urinary tract infection.
is inactive in men with benign prostatic hyperplasia.
is inhibited by selenium and vitamin
is mutated in most men with prostate cancer.
is regulated by androgens.
genetic heterogeneity in the cause of prostate cancer.
a dominant inheritance pattern.
multifocal tumors in affected individuals.
common clinical features associated with all identified genes.
a need for yearly screening in those with a family history.
They inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), the rate-limiting enzyme in cholesterol biosynthesis.
They elevate serum PSA.
A recent meta-analysis found a significant association with reduced prostate cancer incidence.
Statin users tend to be less healthy and medically compliant than nonusers.
Prostate cancer detected in statin users has worse prognosis when stage-matched to controls.
to undergo adjuvant radiation therapy.
that he is at risk of developing a central nervous system tumor.
that his mother was an HPC1 carrier.
to begin serial PSA levels.
to begin immediate hormonal therapy.
prostate cancer in a father or brother.
prostate cancer in a man under age 55.
family history of prostate cancer.
family with two affected members.
prostate cancer in three successive generations.
選擇要在Apple App Store上查看的Topgrade應用程序。